Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$51.24 - $58.89 $56,005 - $64,366
1,093 Added 16.48%
7,724 $411,000
Q2 2022

Aug 11, 2022

BUY
$51.49 - $81.64 $341,430 - $541,354
6,631 New
6,631 $387,000
Q1 2022

May 12, 2022

SELL
$60.03 - $76.49 $688,243 - $876,957
-11,465 Closed
0 $0
Q4 2021

Feb 09, 2022

BUY
$47.97 - $62.21 $57,707 - $74,838
1,203 Added 11.72%
11,465 $690,000
Q3 2021

Nov 10, 2021

SELL
$54.64 - $61.3 $395,429 - $443,628
-7,237 Reduced 41.36%
10,262 $575,000
Q2 2021

Aug 12, 2021

BUY
$59.18 - $69.99 $1.04 Million - $1.22 Million
17,499 New
17,499 $1.06 Million
Q1 2021

May 13, 2021

SELL
$59.31 - $78.82 $959,220 - $1.27 Million
-16,173 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$50.47 - $66.26 $643,946 - $845,411
12,759 Added 373.73%
16,173 $968,000
Q3 2020

Nov 12, 2020

SELL
$51.97 - $63.0 $75,668 - $91,728
-1,456 Reduced 29.9%
3,414 $205,000
Q2 2020

Aug 12, 2020

BUY
$30.8 - $52.47 $149,996 - $255,528
4,870 New
4,870 $256,000
Q1 2020

May 13, 2020

SELL
$28.4 - $50.7 $329,411 - $588,069
-11,599 Closed
0 $0
Q4 2019

Feb 12, 2020

SELL
$36.31 - $46.83 $538,767 - $694,863
-14,838 Reduced 56.13%
11,599 $525,000
Q3 2019

Nov 12, 2019

BUY
$35.66 - $44.99 $110,367 - $139,244
3,095 Added 13.26%
26,437 $1.01 Million
Q2 2019

Aug 12, 2019

BUY
$36.57 - $47.97 $219,493 - $287,915
6,002 Added 34.61%
23,342 $1.02 Million
Q1 2019

May 10, 2019

BUY
$36.47 - $42.17 $307,806 - $355,914
8,440 Added 94.83%
17,340 $660,000
Q4 2018

Feb 11, 2019

BUY
$41.31 - $52.16 $367,659 - $464,223
8,900 New
8,900 $383,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $892M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Alpha Crest Capital Management LLC Portfolio

Follow Alpha Crest Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Crest Capital Management LLC with notifications on news.